“Merck’s Ebola vaccine offered substantial protection to people vaccinated during the 2018-2020 outbreak in the Democratic Republic of the Congo, with an effectiveness of 84% in those who had been vaccinated at least 10 days before being exposed to the virus, a new study reports. An earlier study had shown that people who were vaccinated but went on to develop the disease were more likely to survive the infection.”
From STAT.
“In a historic move, the government of Mali has introduced the human papillomavirus (HPV) vaccine into its routine immunisation programme. During a ceremony held in Bamako earlier this month, and attended by numerous dignitaries and international partners, Gavi and the Ministry of Health and Social Development emphasised the importance of this initiative, terming it a significant step forward in preventing cervical cancer among Malian women.”
From Gavi.
“Measles vaccination has saved 94 million lives globally since 1974. Of those, 92 million were children.”
From Our World in Data.
“Between October 3 and 6, 2024, more than 6.5 million children were vaccinated in a successful synchronized polio campaign between Kenya and Uganda. This cross-border achievement began with a coordinated launch in Bungoma District, Kenya, and Mbale District, Uganda.
Both countries have set an exemplary standard in their recent synchronized polio vaccination campaign conducted this week, which focused on high-risk cross-border regions. By conducting these campaigns on the same dates, sharing real-time information, both countries ensured that children under five in these vulnerable areas were reached effectively, reducing the chance of cross-border virus transmission.”
“Doctors have begun trialling the world’s first mRNA vaccine against the vomiting bug norovirus in the hope the jab could bring huge health and economic benefits.
Norovirus causes sickness and diarrhoea and can spread very rapidly between people who are in close contact, with outbreaks often occurring in hospitals, care homes, schools and nurseries.
While most people recover within two to three days, the virus can be serious, particularly for the very young, elderly or people with a weakened immune system…
Called Nova 301, the phase 3 clinical trial is to run for two years, and will enrol 25,000 adults – with a focus on those over the age of 60 – from countries including Japan, Canada and Australia.”
From The Guardian.
